DelMar Pharmaceuticals, Inc. (DMPI)
| Market Cap | 15.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.90M |
| Shares Out | 11.42M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Aug 19, 2020 |
| Last Price | $1.34 |
| Previous Close | $1.34 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 1.17 - 1.35 |
| Day's Volume | 0 |
| 52-Week Range | 0.38 - 1.53 |
News
SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.
SAN DIEGO, Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor canc...
Shares of nano-cap biopharma DelMar Pharmaceuticals Inc (NASDAQ: DMPI) are trading sharply higher on over 40 times average volume.
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2019 Results - Earnings Call Transcript
About DMPI
DelMar Pharmaceuticals, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. ... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Saiid Zarrabian | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol DMPI |